Last reviewed · How we verify
Lipid Emulsions, Intravenous
Lipid emulsions provide essential fatty acids and calories intravenously to patients unable to receive adequate nutrition orally or enterally.
Lipid emulsions provide essential fatty acids and calories intravenously to patients unable to receive adequate nutrition orally or enterally. Used for Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition, Nutritional support in critically ill patients, Post-operative nutritional support.
At a glance
| Generic name | Lipid Emulsions, Intravenous |
|---|---|
| Also known as | parenteral lipid provision |
| Sponsor | Stanley Dudrick's Memorial Hospital |
| Drug class | Parenteral nutrition supplement |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
Intravenous lipid emulsions are oil-in-water emulsions containing triglycerides, phospholipids, and other lipid components that serve as a source of energy and essential fatty acids (linoleic and alpha-linolenic acid) for parenteral nutrition. They are administered as part of total parenteral nutrition (TPN) regimens to support metabolic needs, particularly in critically ill, post-operative, or malnourished patients who cannot tolerate enteral feeding.
Approved indications
- Parenteral nutrition in patients unable to receive adequate oral or enteral nutrition
- Nutritional support in critically ill patients
- Post-operative nutritional support
- Severe malnutrition requiring intravenous feeding
Common side effects
- Hypertriglyceridemia
- Lipemia
- Phlebitis at infusion site
- Allergic reactions
- Hepatic steatosis with prolonged use
- Thrombocytopenia
Key clinical trials
- Effects of Lipid Emulsions on Coagulation
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Does Intralipid Infusion Can Reverse the Spinal Anesthesia Effect in Day Case Surgery? (NA)
- Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients (PHASE4)
- Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration (PHASE2)
- Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation. (PHASE1, PHASE2)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipid Emulsions, Intravenous CI brief — competitive landscape report
- Lipid Emulsions, Intravenous updates RSS · CI watch RSS
- Stanley Dudrick's Memorial Hospital portfolio CI